Biopharmaceutical News and Research

RSS

SEEK HIV-v vaccine demonstrates 90% reduction in HIV viral load

SEEK, a privately owned biopharmaceutical company specializing in immunology, announces today that it has completed a Phase Ib/II clinical trial of its HIV-v vaccine which demonstrates a one log (approx 90 percent) difference in viral count in HIV-infected people compared with the placebo group, after just a single vaccine injection.

18 Jul 2011

Guizhou Provincial Health Department issues 'Revised Plan' for blood collection stations

China Biologic Products, Inc., a leading plasma-based biopharmaceutical company in China, today announced that the Guizhou Provincial Health Department has issued the revised "Plan for Guizhou Provincial Blood Collection Institutional Setting."

16 Jul 2011

Scientists identify new metabolic pathway for breast cancer

Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the rapidly emerging field of cancer metabolism, announced today a publication in the journal Nature that identifies dysregulated activity of the serine pathway as a novel metabolic target in certain breast cancers.

15 Jul 2011

CVS Caremark adds Access' MuGard to pharmacy benefit network

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that its lead product for oral mucositis, MuGard, has been added to CVS Caremark's pharmacy benefit network.

15 Jul 2011

NeoStem to acquire Amorcyte

NeoStem, Inc., an international biopharmaceutical company, announced the signing of a definitive merger agreement whereby NeoStem will acquire Amorcyte, Inc., a development stage cell therapy company focusing on novel treatments for cardiovascular disease.

15 Jul 2011

Verastem raises $32 million to develop targeted cancer stem cell therapies

Verastem, Inc., a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, announced today that it has raised $32 million through a Series B financing. Proceeds from the financing will support ongoing research and development and will progress drug candidates into clinical development. The first candidate is projected to enter the clinic in 2012.

14 Jul 2011

Accelrys releases Discovery Studio software for biotherapeutics research

Accelrys, Inc., a leading scientific enterprise R&D software and services company, today announced a new release of the Discovery Studio life sciences modeling and simulation software.

14 Jul 2011

Viewpoints: Prominent Republicans against IPAB; docs defend health law; medical marijuana research

The IPAB has created "immediate uncertainty at hand," says Scott & White Healthcare in central Texas, for their 12 hospitals and more than 800 physicians. Many more organizations and associations have expressed similar concerns and urged me to do what I can to repeal this ill-conceived bureaucratic board. That's why I have introduced the Health Care Bureaucrats Elimination Act, and why I'm testifying Wednesday on the other side of the Capitol to build support in the House.

14 Jul 2011

Ipsen, Salk Institute renew Life Sciences Program

Ipsen and The Salk Institute for Biological Studies announced today that they are renewing the Ipsen Life Sciences Program at The Salk Institute.

12 Jul 2011

IGR, IPSEN sign 3 year medical oncology agreement

IPSEN, a global biopharmaceutical company represented by Claude Bertrand, Executive Vice President, R&D and Chief Scientific Officer, and Institut de cancérologie Gustave Roussy, a leading international cancer center represented by Professor Alexander Eggermont, General Director, today announced the signature of a partnership in the area of medical oncology to leverage the combined expertises of their respective R&D teams.

12 Jul 2011

genOway acquires worldwide exclusive license for RMCE technology from bluebird bio for genetically modified rodents

genOway and bluebird bio report today genOway acquisition of an exclusive worldwide license for the RMCE technology (developed at the Massachusetts Institute of Technology) in the field of genetically modified rodents.

12 Jul 2011

NIAID awards $14 million a year for new HIV research

Three research teams focused on developing strategies that could help to rid the body of HIV are receiving grants totaling more than $14 million a year, for up to five years, the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health announced today.

11 Jul 2011

China Biologic receives permit for newly built plasma collection station in Ningyang County

China Biologic Products, Inc., one of the leading plasma-based biopharmaceutical companies in the People's Republic of China, today announced that it has received the permit from the Shandong Province Health Department for the newly built plasma collection station in Ningyang County, Shandong Province, and expects to begin commercial plasma collection at the Ningyang station on July 12, 2011.

11 Jul 2011

Probiomed, Vanda enter license deal to commercialize Fanapt in Mexico

Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced its exclusive license agreement with Probiomed S.A. de C.V., a wholly owned pharmaceutical operating unit of Proquifin S.A. de C.V., for the commercialization of Fanapt in Mexico.

11 Jul 2011

Isogenica opens new automation facility

Isogenica Ltd today announced the opening of a new automation facility at their current location, Chesterford Research Park.

11 Jul 2011

Collaborative research discovers broadly acting antibody against influenza viruses

Annually changing flu vaccines with their hit-and-miss effectiveness may soon give way to a single, near-universal flu vaccine, according to a new report from scientists at The Scripps Research Institute and the Dutch biopharmaceutical company Crucell. They describe an antibody that, in animal tests, can prevent or cure infections with a broad variety of influenza viruses, including seasonal and potentially pandemic strains.

8 Jul 2011

Auxilium reports three year data from XIAFLEX CORDLESS study in Dupuytren's contracture

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced three year recurrence data from the Collagenase Optimal Reduction of Dupuytren's - Long-term Evaluation of Success Study (CORDLESS) for XIAFLEX® (collagenase clostridium histolyticum) in the treatment of adult Dupuytren's contracture patients with a palpable cord.

30 Jun 2011

Biopharmaceutical News and Research

SEEK HIV-v vaccine demonstrates 90% reduction in HIV viral load

Guizhou Provincial Health Department issues 'Revised Plan' for blood collection stations

Scientists identify new metabolic pathway for breast cancer

CVS Caremark adds Access' MuGard to pharmacy benefit network

NeoStem to acquire Amorcyte

Verastem raises $32 million to develop targeted cancer stem cell therapies

Accelrys releases Discovery Studio software for biotherapeutics research

Viewpoints: Prominent Republicans against IPAB; docs defend health law; medical marijuana research

Ipsen, Salk Institute renew Life Sciences Program

IGR, IPSEN sign 3 year medical oncology agreement

genOway acquires worldwide exclusive license for RMCE technology from bluebird bio for genetically modified rodents

NIAID awards $14 million a year for new HIV research

China Biologic receives permit for newly built plasma collection station in Ningyang County

Probiomed, Vanda enter license deal to commercialize Fanapt in Mexico

Isogenica opens new automation facility

Collaborative research discovers broadly acting antibody against influenza viruses

Auxilium reports three year data from XIAFLEX CORDLESS study in Dupuytren's contracture

Sorbent expands $36M Series B financing

Anabasis, Scil Proteins enter license deal for rhNGF to treat eye diseases

Provectus presents additional data on PV-10 at two separate melanoma conferences

Event guide: World ADC San Diego eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News